Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease (Q37293985)

19 August 2017

1 reference

title

Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease (English)

1 reference

19 August 2017

5

Terho Lehtimäki

0 references

Mika Kähönen

2

object named as

Mika Kähönen

0 references

author name string

Tuomo Nieminen

1

1 reference

PubMed ID

18855536

19 August 2017

Leena E Viiri

3

1 reference

PubMed ID

18855536

19 August 2017

Paula Grönroos

4

1 reference

19 August 2017

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

9

1 reference

19 August 2017

10

1 reference

19 August 2017

1475-1486

1 reference

Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man

19 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Abnormal in vivo metabolism of apolipoprotein E4 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein-mediated pathways of lipid antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Polymorphism of apolipoprotein E

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

ApoE plasma levels and risk of cardiovascular mortality in old age

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Frequencies of apolipoprotein E polymorphism in a healthy Kurdish population from Kermanshah, Iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Ezetimibe: cholesterol lowering and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Simvastatin with or without ezetimibe in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Association between apolipoprotein E alleles and autoantibodies against oxidised low-density lipoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein E genotype is related to plasma levels of C-reactive protein and lipids and to longevity in nonagenarians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Association of high sensitive C-reactive protein with apolipoprotein E polymorphism in children and young adults: the Cardiovascular Risk in Young Finns Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Association of apolipoprotein E genotypes with lipid levels and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Independent effects of the -219 G>T and epsilon 2/ epsilon 3/ epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Effect of apolipoprotein E alleles and angiotensin-converting enzyme insertion/deletion polymorphisms on lipid and lipoprotein markers in middle-aged men and in patients with stable angina pectoris or healed myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

An association study of 43 SNPs in 16 candidate genes with atorvastatin response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Improvement of myocardial blood flow by lipid-lowering therapy with pravastatin is modulated by apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Pharmacogenomics of statin responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Clinical implications of pharmacogenomics of statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

The effects of gender and CYP46 and apo E polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients treated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Structural variation in human apolipoprotein E3 and E4: secondary structure, tertiary structure, and size distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein changes: a 21-year follow-up study from childhood to adulthood. The Cardiovascular Risk in Young Finns Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations--the ECTIM Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Regional Differences in Apolipoprotein E Polymorphism in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.10.1475

10.2217/14622416.9.10.1475

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18855536